Skip to content
Inciteful Med
Resources About us Ask a Question

What Is SFT Prognosis and Life Expectancy?

Published: | Updated:

The long-term life expectancy for solitary fibrous tumor (SFT) is generally excellent, especially if the tumor is fully removed. While low-risk tumors rarely spread, SFTs can occasionally return decades later, making lifelong monitoring with your doctor essential.

Key Takeaways

  • • The prognosis for solitary fibrous tumor is generally excellent, especially for low-risk tumors completely removed by surgery.
  • • Doctors use the Demicco Risk Score or WHO grade to predict how your specific tumor might behave based on size, age, and cell activity.
  • • Intermediate and high-risk tumors have a higher chance of returning or spreading, requiring closer monitoring and possibly extra treatments like radiation.
  • • Even if a tumor spreads, patients can often live for many years or decades because solitary fibrous tumors usually grow slowly.
  • • Lifelong follow-up scans are necessary for everyone with a solitary fibrous tumor because recurrences can happen up to 20 years later.

The long-term prognosis for Solitary Fibrous Tumor (SFT) is generally excellent, especially if the tumor was completely removed during surgery and is classified as “low-risk” [1][2]. However, because SFTs can sometimes behave unpredictably, your individual outlook depends heavily on how the tumor was graded by the pathologist [3][4]. While many patients go on to live a normal lifespan without ever experiencing a recurrence, intermediate and high-risk tumors have a higher chance of returning and require much closer monitoring [5][6].

Understanding Risk Scores: The Demicco Score and WHO Grade

Because SFTs are rare and can occur almost anywhere in the body, doctors rely on specialized scoring systems to predict how the tumor is likely to behave. For tumors outside the brain and spinal cord, the most widely used tool is the Demicco Risk Score (often called the D-score) [7][8]. For tumors located in the central nervous system, doctors typically use the WHO grade [9][10].

The Demicco score calculates your risk by looking at four specific factors from your pathology report [11][12]:

  • Patient age: Being age 55 or older slightly increases the risk score.
  • Tumor size: Tumors larger than 5 centimeters (about 2 inches) slightly increase the risk score, while tumors larger than 15 centimeters (about 6 inches) carry an even higher risk.
  • Mitotic count: This is the number of actively dividing cells the pathologist sees under a microscope. A higher count (often defined as 4 or more per 10 high-power fields) means the tumor is growing faster [6].
  • Tumor necrosis: This refers to areas of dead tissue within the tumor, which can be a sign of aggressive growth [13].

Based on these factors, the tumor is assigned a score that classifies it into a risk category. Recently, doctors have also begun looking for specific genetic markers, such as TERT promoter mutations or TP53 mutations, which are strongly linked to more aggressive tumors and a higher chance of recurrence [14][15].

Outcomes Based on Risk Level

Low-Risk, Completely Resected Tumors

If your tumor was completely removed with clear surgical margins (an “R0 resection”) and has a low Demicco score or WHO grade, your long-term prognosis is very favorable [16][2]. Research shows that the risk of a low-risk SFT spreading (metastasizing) within 10 years is very low, typically estimated at less than 5% to 10% [6]. The vast majority of people in this category are effectively cured by surgery alone, though they still require regular follow-up scans [17].

Note: Even if a tumor is low-risk, if the surgeon was unable to remove it entirely (leaving “positive margins,” known as an R1 or R2 resection), your doctor may recommend radiation therapy to reduce the risk of it growing back in that same spot [18][19].

Intermediate and High-Risk Tumors

Tumors classified as intermediate or high-risk, or WHO grade 3, have a higher likelihood of local recurrence (returning to the same spot) or distant metastasis (spreading to other organs, such as the lungs, liver, or bones) [20][21]. Studies indicate that the 10-year risk of metastasis is roughly 40% for intermediate-risk and up to 70% for high-risk tumors [6].

While these statistics can sound frightening, it is important to understand that metastasis does not immediately mean a loss of life. Even for high-risk tumors, overall survival is frequently measured in many years or decades [22][23]. SFTs typically grow slowly, and if the tumor does return or spread, there are treatments available to manage the disease long-term. This can include additional surgeries, targeted radiation, or systemic therapies like anti-angiogenic medications (such as pazopanib) that help slow the tumor’s growth [24][25].

Because of this higher risk, your medical team will monitor you much more closely. If the tumor is high-risk, your doctor may recommend additional treatments right after surgery, such as radiation therapy, to help prevent the tumor from coming back [26][18].

The Need for Lifelong Monitoring

One of the most important things to know about SFTs is that they have the potential for very late recurrences. Unlike some other tumors that are considered “cured” if they haven’t returned after 5 years, an SFT can occasionally recur 10, 15, or even 20 years after the initial surgery [27][28][29].

For this reason, lifelong clinical and imaging follow-up is universally recommended, regardless of whether your tumor was low, intermediate, or high risk [30][31]. This usually involves regular imaging, such as CT or MRI scans of the chest, abdomen, or the original tumor site, every 6 to 12 months for the first few years, and then eventually transitioning to annual scans. Regular monitoring ensures that if the tumor ever does return, it is caught early when it is small and most treatable.

Frequently Asked Questions

How do doctors determine if my solitary fibrous tumor is high risk?
Doctors use scoring systems like the Demicco Score or WHO grade to determine your risk. They look at your age, the tumor's size, how fast the cells are dividing, and if there is any dead tissue within the tumor.
Will a solitary fibrous tumor come back after surgery?
While many low-risk tumors never return after complete surgical removal, solitary fibrous tumors can sometimes recur 10 to 20 years later. This is why lifelong monitoring with regular imaging scans is universally recommended for all patients.
What happens if my solitary fibrous tumor spreads?
If the tumor spreads or returns, it does not immediately mean a loss of life, as these tumors usually grow slowly. Treatments like additional surgery, targeted radiation, or medications like pazopanib can help manage the disease long-term.
What is the Demicco score on my pathology report?
The Demicco score is a risk assessment tool used for solitary fibrous tumors located outside the brain and spinal cord. It calculates your risk of the tumor returning by analyzing your age, tumor size, mitotic count, and tumor necrosis.

Questions for Your Doctor

  • • Can you help me calculate my exact Demicco Risk Score or WHO grade based on my pathology report?
  • • Were the surgical margins completely clear (an R0 resection), or is there a need to discuss radiation therapy?
  • • Was my tumor tested for TERT promoter or TP53 mutations, and if not, would that information change my treatment plan?
  • • What specific imaging schedule (like CT or MRI scans) do you recommend for my long-term monitoring, and who will manage those orders years from now?
  • • If my tumor is intermediate or high-risk, should we consult with a sarcoma specialist to discuss potential adjuvant treatments or clinical trials?

Questions for You

  • • Am I prepared to commit to lifelong follow-up scans, and do I have a reliable way to remind myself to schedule them every year?
  • • How is my anxiety regarding recurrence affecting my daily life, and would I benefit from joining a support group or speaking with a counselor?
  • • Who on my current medical team (surgeon, oncologist, or primary care doctor) do I trust most to coordinate my long-term surveillance?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A giant solitary fibrous tumour of the liver: a case report.

    Roman J, Vávra P, Vávrová M, et al.

    Acta chirurgica Belgica 2023; (123(1)):90-93 doi:10.1080/00015458.2021.1932180.

    PMID: 34006182
  2. 2

    Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification May Better Predict Patient outcome.

    Machado I, Nieto Morales MG, Cruz J, et al.

    International journal of molecular sciences 2021; (22(17)) doi:10.3390/ijms22179423.

    PMID: 34502329
  3. 3

    Malignant extrapleural solitary fibrous tumor arising in the sublingual gland: A case report and review of literature.

    Iorio B, Ronchi A, Montella M, et al.

    Oral oncology 2019; (90()):141-144 doi:10.1016/j.oraloncology.2018.12.013.

    PMID: 30638760
  4. 4

    Intracranial solitary fibrous tumor/hemangiopericytomas: a clinical analysis of a series of 17 patients.

    Chenhui Z, He G, Wu Z, et al.

    British journal of neurosurgery 2024; (38(3)):617-624 doi:10.1080/02688697.2021.1944980.

    PMID: 34334066
  5. 5

    Grade III solitary fibrous tumor/hemangiopericytoma: An enthralling intracranial tumor-A case report and literature review.

    Al Armashi AR, Alkrekshi A, Al Zubaidi A, et al.

    Radiology case reports 2022; (17(10)):3792-3796 doi:10.1016/j.radcr.2022.07.007.

    PMID: 35965927
  6. 6

    Metastatic Patterns of Solitary Fibrous Tumors: A Single-Institution Experience.

    O'Neill AC, Tirumani SH, Do WS, et al.

    AJR. American journal of roentgenology 2017; (208(1)):2-9 doi:10.2214/AJR.16.16662.

    PMID: 27762594
  7. 7

    Solitary Fibrous Tumors of the Female Genital Tract: A Study of 27 Cases Emphasizing Nonvulvar Locations, Variant Histology, and Prognostic Factors.

    Devins KM, Young RH, Croce S, et al.

    The American journal of surgical pathology 2022; (46(3)):363-375 doi:10.1097/PAS.0000000000001829.

    PMID: 34739418
  8. 8

    Risk factors for recurrent disease after resection of solitary fibrous tumor: a systematic review.

    Tolstrup J, Loya A, Aggerholm-Pedersen N, et al.

    Frontiers in surgery 2024; (11()):1332421 doi:10.3389/fsurg.2024.1332421.

    PMID: 38357190
  9. 9

    Clinical outcomes of solitary fibrous tumors and hemangiopericytomas and risk factors related to recurrence and survival based on the 2021 WHO classification of central nervous system tumors.

    Wu Y, Zhao T, Cai Y, et al.

    Journal of neurosurgery 2024; (140(1)):69-79 doi:10.3171/2023.4.JNS23147.

    PMID: 37310060
  10. 10

    Solitary fibrous tumor of thoracic cavity, extra-thoracic sites and central nervous system: Clinicopathologic features and association with local recurrence and metastasis.

    Alexiev BA, Finkelman BS, Streich L, et al.

    Pathology, research and practice 2021; (224()):153531 doi:10.1016/j.prp.2021.153531.

    PMID: 34171600
  11. 11

    Prognostic usefulness of a modified risk model for solitary fibrous tumor that includes the Ki-67 labeling index.

    Sugita S, Segawa K, Kikuchi N, et al.

    World journal of surgical oncology 2022; (20(1)):29 doi:10.1186/s12957-022-02497-2.

    PMID: 35105348
  12. 12

    Toward Better Understanding and Management of Solitary Fibrous Tumor.

    Kazazian K, Demicco EG, de Perrot M, et al.

    Surgical oncology clinics of North America 2022; (31(3)):459-483 doi:10.1016/j.soc.2022.03.009.

    PMID: 35715145
  13. 13

    Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

    Demicco EG, Wagner MJ, Maki RG, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(10)):1433-1442 doi:10.1038/modpathol.2017.54.

    PMID: 28731041
  14. 14

    TERT promoter mutations and prognosis in solitary fibrous tumor.

    Bahrami A, Lee S, Schaefer IM, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(12)):1511-1522 doi:10.1038/modpathol.2016.126.

    PMID: 27562490
  15. 15

    Case Report: Molecular Characterization of Aggressive Malignant Retroperitoneal Solitary Fibrous Tumor: A Case Study.

    Nonaka H, Kandori S, Nitta S, et al.

    Frontiers in oncology 2021; (11()):736969 doi:10.3389/fonc.2021.736969.

    PMID: 35004271
  16. 16

    Presentation of Infantile Hemangiopericytoma/Solitary Fibrous Tumor as a Giant Extracranial Temporal Mass.

    Boynuyogun E, Calis M, Kavuncuoglu A, et al.

    Fetal and pediatric pathology 2021; (40(5)):523-527 doi:10.1080/15513815.2020.1716904.

    PMID: 31994965
  17. 17

    Metastasis of a Solitary Fibrous Tumor in the Mandible: A Case Report.

    Dudde F, Giese M, Henkel KO

    Cancer diagnosis & prognosis 2023; (3(1)):107-114 doi:10.21873/cdp.10187.

    PMID: 36632580
  18. 18

    Extrameningeal solitary fibrous tumors-surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet.

    Haas RL, Walraven I, Lecointe-Artzner E, et al.

    Cancer 2020; (126(13)):3002-3012 doi:10.1002/cncr.32911.

    PMID: 32315454
  19. 19

    Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?

    Haas RL, Walraven I, Lecointe-Artzner E, et al.

    Acta oncologica (Stockholm, Sweden) 2021; (60(1)):35-41 doi:10.1080/0284186X.2020.1826574.

    PMID: 32988268
  20. 20

    Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis.

    Yamashita D, Suehiro S, Kohno S, et al.

    Neurosurgical review 2021; (44(3)):1591-1600 doi:10.1007/s10143-020-01348-6.

    PMID: 32671693
  21. 21

    Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature.

    Lavacchi D, Antonuzzo L, Briganti V, et al.

    Anti-cancer drugs 2020; (31(6)):646-651 doi:10.1097/CAD.0000000000000900.

    PMID: 31972591
  22. 22

    Recurrence of Solitary Fibrous Tumour of the Pleura: A 20-Years Bi-centric Study with Risk Score Comparison.

    Gagnepain E, Clermidy H, Drevet G, et al.

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2025; (67(11)) doi:10.1093/ejcts/ezaf350.

    PMID: 41071042
  23. 23

    Evaluation of Alternative Risk Stratification Systems in a Large Series of Solitary Fibrous Tumors with Molecular Findings and Ki-67 Index Data: Do They Improve Risk Assessment?

    Machado I, Blázquez Bujeda Á, Giner F, et al.

    International journal of molecular sciences 2022; (24(1)) doi:10.3390/ijms24010439.

    PMID: 36613891
  24. 24

    Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

    Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al.

    The Lancet. Oncology 2019; (20(1)):134-144 doi:10.1016/S1470-2045(18)30676-4.

    PMID: 30578023
  25. 25

    Soft Tissue Solitary Fibrous Tumor: Combined Surgery and Radiation Therapy Results in Excellent Local Control.

    Bishop AJ, Zagars GK, Demicco EG, et al.

    American journal of clinical oncology 2018; (41(1)):81-85 doi:10.1097/COC.0000000000000218.

    PMID: 26270446
  26. 26

    Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients.

    Li Q, Deng W, Sun P

    World neurosurgery 2022; (166()):e60-e69 doi:10.1016/j.wneu.2022.06.089.

    PMID: 35760325
  27. 27

    A case of primary orbital solitary fibrous tumor with lung metastases 41 years after initial treatment.

    Tanabe M, Yoshikawa H, Yamada Y, et al.

    Orbit (Amsterdam, Netherlands) 2022; (41(6)):810-814 doi:10.1080/01676830.2021.1954665.

    PMID: 34261401
  28. 28

    Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

    Sagiv O, Bell D, Guo Y, et al.

    Ophthalmic plastic and reconstructive surgery 2019; (35(2)):148-154 doi:10.1097/IOP.0000000000001189.

    PMID: 30371551
  29. 29

    Long-Term Surgical Outcome for Orbital Solitary Fibrous Tumors.

    Vahdani K, Rose GE, Verity DH

    Ophthalmic plastic and reconstructive surgery 2023; (39(6)):606-613 doi:10.1097/IOP.0000000000002446.

    PMID: 37405750
  30. 30

    Solitary fibrous tumor of the kidney: A case report.

    Zaghbib S, Chakroun M, Essid MA, et al.

    International journal of surgery case reports 2019; (62()):112-114 doi:10.1016/j.ijscr.2019.08.004.

    PMID: 31494455
  31. 31

    Solitary Fibrous Tumour: A Single Institution Retrospective Study and Further Validation of a Prognostic Risk Assessment System.

    Friis RB, Safwat A, Baad-Hansen T, Aggerholm-Pedersen N

    Clinical oncology (Royal College of Radiologists (Great Britain)) 2018; (30(12)):798-804 doi:10.1016/j.clon.2018.08.015.

    PMID: 30206022

This page explains solitary fibrous tumor prognosis and scoring systems for educational purposes. Always consult your oncologist to understand your specific life expectancy and individual risk.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.